Epidemiology and Prognostic Analysis of Chinese Cancer Patients With Cancer-related Fatigue

This investigator-initiated study aims to evaluate the incidence and severity of cancer-related fatigue (CRF) in patients with malignant tumors, to analyze the influencing factors of CRF, and to explore its impact on anti-tumor treatment and prognosis. Using patient-completed questionnaires, combined with outpatient visit records and telephone follow-up, this study will explore the following aspects:

Assess the incidence and severity of cancer-related fatigue in patients with malignant tumors.

Analyze the influencing factors of cancer-related fatigue, including tumor type, treatment regimen, disease stage, efficacy of anti-tumor therapy, adverse events associated with anti-tumor therapy, and concomitant medications.

Evaluate the impact of cancer-related fatigue on anti-tumor treatment and prognosis.

Assess the multidimensional state and severity of cancer-related fatigue in patients with malignant tumors using the Brief Fatigue Inventory - Cancer (BFI-C) and the Multidimensional Fatigue Symptom Inventory - Short Form (MFSI-SF).

By collecting patients' medical information, including imaging and laboratory results, as well as outpatient and telephone follow-up records, this study will explore the following aspects:

Evaluate the impact of different degrees of cancer-related fatigue on the prognosis of patients with malignant tumors.

Explore the impact of the efficacy of anti-tumor therapy on the multidimensional state and severity of cancer-related fatigue in patients.

Inclusion criteria

• Male or female, aged 18 years or older.
• Able to understand the purpose of this survey study, willing to participate, and able to sign an informed consent form.
• Malignant tumor confirmed histologically or cytologically.

Exclusion criteria

• Pregnant or breastfeeding women.
• Patients with acute or chronic infections, or those with other serious medical conditions that, in the investigator's judgment, make them unsuitable for this study.
• Patients with two or more concurrent malignant tumors (excluding the following: cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and papillary thyroid carcinoma).
• Patients with psychiatric illness or mental disorders, poor compliance, or who are unable to cooperate and report treatment responses.
• Patients with severe organic disease or major organ failure, such as decompensated heart, lung, liver, or kidney failure.
• Patients with other conditions that, in the investigator's opinion, make them unsuitable for participation in this study.